Index Entries

Ali Shalash, Nourhan Belal, Amr S. Zaki, Shady S. Georgy, Mohamed Fahmy Doheim, Ahmed Hazzou, and Azza Abdelnasser
December 9, 2022
The Egyptian Journal of Neurology, Psychiatry and Neurosurgery
Ain Shams University (Egypt)

"Discussion: In this case series, six males and one female with ages ranging from 29 to 59 years were presented with variable GBS manifestations from December 2021 to February 2022. Three patients received the AstraZeneca vaccine, two received the Pfizer vaccine, one received the Sinopharm and one received Janssen vaccine. Latency ranged from 5 to 60 days and cases achieved either partial or complete improvement after plasmapheresis. In a review of 19 cases with GBS post-vaccination, there was a high variability in the latency between vaccination and onset of GBS following COVID-19 vaccinations and mild to severe complications with six patients requiring mechanical ventilation. Although the outcome was favorable, partial recovery only was achieved ...

The current report confirms the favorable response of post-COVID-19 immunization to plasmapheresis, rather than IV methylprednisolone. Recent studies reported more frequent use of IVIG, with less frequent use of plasmapheresis and rare use of steroids. Similar to thesis reports, plasmaphereses showed favorable outcome. Plasmapheresis was used as it is more affordable and available."

document
adverse events,clinical cases,COVID-19,demyelination,neurological disorders,vaccines